분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-11-14 17:58:34 , Hit : 1135
 Gilead hepatitis C drug highly effective in cirrhosis patients


Reuters
By Ransdell Pierson
November 11, 2014 11:29 AM


      
By Ransdell Pierson

(Reuters) - Gilead Sciences Inc on Tuesday said its new Harvoni drug for hepatitis C achieved cure rates of 96 percent to 97 percent in a study of patients who had cirrhosis and had failed to benefit from prior treatments.

The data bolsters the attractiveness of Harvoni, a combination drug that U.S. regulators approved last month and whose $95,000 cost for a course of treatment has raised complaints from insurers and politicians.

The Gilead study involved 155 patients with cirrhosis and the most common genotype 1 form of the liver virus. They previously had failed to benefit from standard older treatments that included protease inhibitors as well as interferon and ribavirin, drugs that can cause harsh side effects and must be taken for almost a year.

All patients received Harvoni, a once-daily pill containing Gilead's Sovaldi and ledipasvir. The combination eliminates the need to take interferon and ribavirin with Sovaldi.

In one group taking Harvoni alone for 24 weeks, the cure rate was 97 percent. It was 96 percent for patients who received Harvoni plus ribavirin for 12 weeks.

Three far smaller Gilead studies evaluated Sovaldi, a so-called nucleotide, in combination with the company's experimental NS5A inhibitor GS-5816, with and without ribavirin for eight or 12 weeks.

Of patients taking the combination for 12 weeks without ribavirin, sustained cures were seen in 100 percent of genotype 1 patients, with and without cirrhosis, and in 88 percent of those with the less common genotype 3 form of the virus, with cirrhosis.

Shares of Gilead were up 1.4 percent at $108.54 in morning trading.

(Reporting by Ransdell Pierson; Editing by Lisa Von Ahn)







1127   항체를 이용한 HIV치료법  이성욱 2015/04/15 1109
1126   HIV에 방어하는 박테리아가 인체에 존재한다?  이성욱 2015/10/12 1111
1125   영국 의회, `세 부모 아기` 합법화  이성욱 2015/02/06 1112
1124   iPS세포 '미니 간' 대량생산장치 개발  이성욱 2015/02/23 1112
1123   C형 간염에 보다 효과적인 새로운 복합제  이성욱 2015/11/24 1117
1122   한국의 MERS가 글로벌 보건을 위협할 수 있을까?  이성욱 2015/06/09 1126
1121   유전자 조작인간배아를 만들어낸 중국과학자들  이성욱 2015/04/27 1131
1120   DNA 앰블런스  이성욱 2015/07/30 1131
1119   세균의 도구로 식물 DNA 편집  이성욱 2015/06/09 1132
1118   Off Switch Found for Common Version of the CRISPR-Cas9 System  이성욱 2017/01/02 1132
1117   2018 Lasker Award Winners: Gene Expression Researchers, Propofol Discoverer, Pioneer for RNA Biology, and Women in STEM  이성욱 2018/09/12 1132
1116   A single gene turns colorectal cancer cells back into normal tissue in mice  이성욱 2015/06/23 1133
  Gilead hepatitis C drug highly effective in cirrhosis patients  이성욱 2014/11/14 1135
1114   인간배아 DNA편집을 둘러싼 논란  이성욱 2015/03/17 1136
1113   세부모 배아의 대안적 방법  이성욱 2015/04/29 1136
1112   Beyond CRISPR Cuts: Five Complements To Cas9  이성욱 2017/02/24 1136
1111   Drug flushes out hidden AIDS virus  이성욱 2015/03/07 1140
1110   유전자 가위, 매머드 복원-안전한 백신의 시대 리본 자르다  이성욱 2016/03/14 1140
1109   화성의 물에서 생명체를 찾는 것의 어려움  이성욱 2015/10/01 1148
1108   Fixing CRISPR  이성욱 2017/06/27 1149

[1][2][3][4][5][6][7] 8 [9][10]..[64] [다음 10개]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN